BioNTech and Pfizer have filed a request to register a COVID-19 vaccine in the US

US pharmaceutical giant Pfizer and German BioNTech submitted a request to the US food and drug administration (FDA) on Friday to obtain permission for the COVID-19 vaccine’s emergency use, CNBC reported.

The process of processing the request with the FDA is expected to take several weeks. According to the TV channel, the Advisory Committee’s meeting for testing the vaccine is tentatively scheduled for early December. “Some Americans may get their first dose of the vaccine in about a month,” CNBC points out.

Earlier on Friday, Biotech and Pfizer said they had already submitted a preliminary application for the review process to regulators worldwide, including Australia, Canada, European countries, Japan, and the UK. Further requests to other regulators are planned to be submitted soon.

The final analysis of data from clinical trials of the CAVID-19 vaccine by Pfizer and BioNTech showed its effectiveness at 95%.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Author: Ivan Maltsev
The study of political and social problems of different countries of the world. Analysis of large companies on the world market. Observing world leaders in the political arena.
Function: Chief-Editor
Ivan Maltsev

Spelling error report

The following text will be sent to our editors: